Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Lu-DOTA-TATE in Newly Diagnosed Advanced GEP-NET (NETTER-3)
NCT06784752Phase 3Recruiting
- Sponsor
- Novartis
- Start
- May 2025
- Primary completion
- Dec 2028
- Modality
- Peptides, Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of lutetium Lu 177 dotatate in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Novartis. Started May 2025; status: recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT06784752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06784752.